Early diagnosis and prompt treatment of all persons with any form of drug-susceptible
or drug-resistant TB is fundamental. An understanding of the health-care providers initially approached by people with TB, the tests used for diagnosing TB, and the delays people encounter in receiving diagnoses is essential to the design and implementation of interventions.
WHO-endorsed rapid TB diagnostics and DST should be available to all who need it, in line with the first pillar of the End TB Strategy. A Framework of indicators and targets has been developed to guide countries in increasing access to early detection of TB using rapid diagnostics, achieve universal DST and ensure quality of testing.
News and events
A framework of indicators and targets has been launched measuring programmes’ capacity to detect TB using new diagnostics, provide universal DST, and ensure the quality of testing under the End TB Strategy.
Rapid diagnostic test and shorter, cheaper treatment signal new hope for multidrug-resistant tuberculosis patients
New WHO recommendations aim to speed up detection and improve treatment outcomes for multidrug resistant tuberculosis (MDR-TB) through use of a novel rapid diagnostic test and a shorter, cheaper treatment regimen.
Tests based on the detection of mycobacterial lipoarabinomannan (LAM) antigen in urine have emerged as potential point-of-care tests for TB. WHO has issued recommendations on the use of a lateral flow LAM assay for the diagnosis and screening of active TB in people living with HIV.
Bridging the growing gap between diagnosis and treatment in multidrug-resistant tuberculosis (MDR-TB)
An unprecedented scale-up in test development and laboratory strengthening has been seen since 2009, when the World Health Assembly called for universal access to tuberculosis (TB) drug susceptibility testing (DST) and treatment of all patients with drug-resistant disease.
- WHO policies on diagnostics and laboratory strengthening
- WHO Framework of indicators and targets for laboratory strengthening
- Framework for implementing TB diagnostics
- High-priority target product profiles for new tuberculosis diagnostics
Policy guidance on the molecular second-line line-probe assay